Director, Scleroderma Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Professor of Medicine
Feinberg School of Medicine
Director, Interstitial Lung Disease Program
Division of Pulmonary and Critical Care Medicine
Associate Professor and Director of the Interstitial Lung Disease Program
University of Utah
Salt Lake City, Utah
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
Rheumatologists, pulmonologists, dermatologists, and other healthcare professionals who may encounter and/or treat patients with SSc-ILD.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 30, 2019, through September 30, 2020:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Pooled data from ACR 2019, reported by CCO, analyzing the safety of filgotinib, an investigational JAK1 inhibitor, through 24 weeks of treatment in patients with RA
Audio: New Crohn’s and ulcerative colitis clinical data from ACG and DDW 2018. From Francis A. Farraye, MD, MSc.
Full IBD slides: New Crohn’s and ulcerative colitis clinical data from ACG and DDW 2018. From Francis A. Farraye, MD, MSc.
Emerging Crohn’s and ulcerative colitis treatments and targets: integrins, JAK inhibitors, IL-12/23 inhibitors, S1P1 modulators, fecal transplant (FMT)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.